中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO OF STRATEGIC COOPERATION AGREEMENT

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**" or "**Ab&B Bio-Tech**", together with its subsidiary, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that on March 13, 2026, the Company has entered into a strategic cooperation agreement for overseas market expansion of subunit influenza vaccine (the "**Strategic Cooperation Agreement**") with Walvax Hong Kong Limited ("**Walvax Hong Kong**").

STRATEGIC COOPERATION AGREEMENT

Pursuant to the Strategic Cooperation Agreement, the parties will engage in in-depth cooperation in respect of the overseas market registration, sales and commercialisation of the products developed by the Group. The core product for overseas expansion is the trivalent subunit influenza vaccine (Huierkangxin 3) (the "**Product**") independently developed by the Group. The Product was approved for marketing in January 2026 and is the first and only trivalent subunit influenza vaccine in China applicable to the entire population aged 6 months and above.

REASONS FOR AND BENEFITS OF ENTERING INTO THE STRATEGIC COOPERATION AGREEMENT

The Board believes that Walvax Hong Kong is a pioneer in overseas business growth and possesses a strong portfolio of international operating experience. Through this cooperation, the Company will leverage Walvax Hong Kong's overseas market resources and well-established distribution networks, which have been cultivated over many years, to accelerate the expansion of its products into Southeast Asia, Latin America, the Middle East and other markets in the Southern Hemisphere.

INFORMATION ON WALVAX BIOTECHNOLOGY CO., LTD.

Walvax Hong Kong is a wholly-owned subsidiary of Walvax Biotechnology Co., Ltd.("**Walvax Biotech**") (stock code: 3000142. SZ). Founded in 2001, Walvax Biotech is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality traditional vaccines and innovative vaccines. With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, Walvax Biotech produces efficacious, quality, innovative and affordable products to protect people from the world's deadliest diseases, for the purpose of helping everyone live a healthy life.

The Strategic Cooperation Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), nor does it constitute a connected transaction under Chapter 14A of the Listing Rules. Shareholders and investors are reminded that the transactions contemplated under the Strategic Cooperation Agreement are still pending the conclusion of a definitive business agreement. If a definitive business agreement is entered into, the Company will make further announcements in accordance with the Listing Rules as necessary or appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of our Board and general manager

Hong Kong, March 13, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.